Deborah Norman Farlow PhD

Dr. Farlow has more than a decade of experience in clinical research in a wide range of therapeutic areas in the Pharmaceutical Industry and in Academia. At Akili, Dr. Farlow is responsible for Clinical Research across all Investigator Initiated programs and leads Clinical Operations for all studies in the Affective/ MDD Program. Prior to joining Akili, she spent 8 years at the Broad Institute of MIT and Harvard leading many large discovery efforts, most notably the NHLBI’s Candidate Gene Association Resource (CARe) and the NIMH’s Alzheimer’s Disease Sequencing Project (ADSP).

Before joining the Broad Institute, Dr. Farlow spent 5 years at Millennium Pharmaceuticals driving gene discovery efforts within the Bayer-Millennium Drug Discovery Partnership within the Virology, Hematology, and Cardiovascular collaborative focus areas. She received her Ph.D. in Molecular Biology with an emphasis in Genomics at the Rockefeller University where her research focused on neuronal degeneration and its underlying genetic causes. Dr. Farlow was awarded the E.B. Squibb Prize for Best Undergraduate Thesis in Molecular Biology and her A.B. degree with Honors from Princeton University.